Advertisement
Screener

iSpecimen Inc. (ISPC) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

2.8 / 5 stars · 68/120 Roast Me

iSpecimen Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

iSpecimen Inc. (ISPC) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.04 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-04-01

  • iSpecimen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $3.04M, a 19.20% decline from fiscal 2023.
  • iSpecimen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $3.77M, a 37.38% increase from fiscal 2022.
  • iSpecimen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.74M, a 204.78% increase from fiscal 2021.
  • iSpecimen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $900.00K.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month
2024-12-31$3.04M
10-K · filed 2026-04-01
2023-12-31$3.77M
10-K · filed 2024-03-13
2022-12-31$2.74M
10-K/A · filed 2023-03-30
2021-12-31$900.00K
10-K · filed 2022-03-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14